Is semaglutide based on beta a

4
Comment
Favorite

Simplyff
2025-11-24

Is semaglutide based on beta amyloid

Novo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal

Novo Nordisk A/S announced the top-line results from the two-year primary analysis of the evoke and evoke+ phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimer's disease. The trials, which enrolled a total of 3,808 adults, did not demonstrate a statistically significant reduction in Alzheimer's disease progression compared to placebo, as measured by the Clinical Dementia Rating - Sum of Boxes score. While improvements in Alzheimer's disease-related biomarkers were observed, these did not translate into a delay in disease progression. The 1-year extension period for both trials will be discontinued based on these efficacy results. Topline results will be presented at the Clinical Trials in Alzheimer's Disease conference on December 3, 2025, with full results scheduled for presentation at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026.Disclaimer: This news brief was created by Public Technologies using generative artificial intellig

Novo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":503646541824856,"tweetId":"503646541824856","gmtCreate":1763983781865,"gmtModify":1763983785854,"author":{"id":3574372094453157,"idStr":"3574372094453157","authorId":3574372094453157,"authorIdStr":"3574372094453157","name":"Simplyff","avatar":"https://static.tigerbbs.com/05c58f96d15fed49360206c98a4ba71c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.16","exceedPercentage":"93.20%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>Is semaglutide based on beta amyloid</p></body></html>","htmlText":"<html><head></head><body><p>Is semaglutide based on beta amyloid</p></body></html>","text":"Is semaglutide based on beta amyloid","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/503646541824856","repostId":2585295466,"repostType":2,"repost":{"id":"2585295466","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1763983625,"share":"https://ttm.financial/m/news/2585295466?lang=en_US&edition=fundamental","pubTime":"2025-11-24 19:27","market":"us","language":"en","title":"Novo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2585295466","media":"Reuters","summary":"Novo Nordisk A/S announced the top-line results from the two-year primary analysis of the evoke and evoke+ phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimer's disease. The trials, which enrolled a total of 3,808 adults, did not demonstrate a statistically significant reduction in Alzheimer's disease progression compared to placebo, as measured by the Clinical Dementia Rating - Sum of Boxes  score. While improvements in Alzheimer's disease-related biomarkers were observed, these did not translate into a delay in disease progression. The 1-year extension period for both trials will be discontinued based on these efficacy results. Topline results will be presented at the Clinical Trials in Alzheimer's Disease  conference on December 3, 2025, with full results scheduled for presentation at the 2026 Alzheimer's and Parkinson's Diseases Conferences  in March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellig","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer&#39;s patients, sending its share price down 12%.</p><p>The data is key for Novo because Alzheimer&#39;s disease would be a large new market for GLP-1 medicines like semaglutide after blockbuster success in the treatment of obesity and diabetes. Alzheimer&#39;s patients currently have limited treatment options.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f9b813f79a81792c6d188794857551a0\" title=\"\" tg-width=\"358\" tg-height=\"106\"/></p><p>The drug being tested is Novo&#39;s Rybelsus, a pill currently approved only for treatment of type 2 diabetes. Both Rybelsus and Novo&#39;s blockbuster drugs Ozempic and Wegovy are based on the same active ingredient, semaglutide, a GLP-1 medicine.</p><p>&#34;While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer&#39;s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,&#34; Chief Scientific Officer Martin Holst Lange said in a statement.</p><p>The results from the two trials of early-stage patients, called EVOKE and EVOKE+, mark another setback for the Danish drugmaker, which boomed on the success of blockbuster medicine Wegovy before slowing sales growth and a tumbling share price prompted a CEO change and mass layoffs.</p><p>The setback reinforces analyst scepticism about Novo&#39;s Alzheimer&#39;s ambitions, with UBS having estimated just a 10% probability of success.</p><p>The company&#39;s Executive Vice President for Product and Portfolio Strategy Ludovic Helfgott had described the Alzheimer&#39;s trials as a &#34;lottery ticket&#34; in September, a reference to its uncertain prospects yet huge potential.</p><p>Alzheimer&#39;s disease and other dementias affect more than 55 million people globally. There is no cure.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Shares Drop 12% After Alzheimer's Drug Trial Fails to Meet Main Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 19:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer&#39;s patients, sending its share price down 12%.</p><p>The data is key for Novo because Alzheimer&#39;s disease would be a large new market for GLP-1 medicines like semaglutide after blockbuster success in the treatment of obesity and diabetes. Alzheimer&#39;s patients currently have limited treatment options.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f9b813f79a81792c6d188794857551a0\" title=\"\" tg-width=\"358\" tg-height=\"106\"/></p><p>The drug being tested is Novo&#39;s Rybelsus, a pill currently approved only for treatment of type 2 diabetes. Both Rybelsus and Novo&#39;s blockbuster drugs Ozempic and Wegovy are based on the same active ingredient, semaglutide, a GLP-1 medicine.</p><p>&#34;While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer&#39;s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,&#34; Chief Scientific Officer Martin Holst Lange said in a statement.</p><p>The results from the two trials of early-stage patients, called EVOKE and EVOKE+, mark another setback for the Danish drugmaker, which boomed on the success of blockbuster medicine Wegovy before slowing sales growth and a tumbling share price prompted a CEO change and mass layoffs.</p><p>The setback reinforces analyst scepticism about Novo&#39;s Alzheimer&#39;s ambitions, with UBS having estimated just a 10% probability of success.</p><p>The company&#39;s Executive Vice President for Product and Portfolio Strategy Ludovic Helfgott had described the Alzheimer&#39;s trials as a &#34;lottery ticket&#34; in September, a reference to its uncertain prospects yet huge potential.</p><p>Alzheimer&#39;s disease and other dementias affect more than 55 million people globally. There is no cure.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLtX36C:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2585295466","content_text":"Novo-Nordisk A/S said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients, sending its share price down 12%.The data is key for Novo because Alzheimer's disease would be a large new market for GLP-1 medicines like semaglutide after blockbuster success in the treatment of obesity and diabetes. Alzheimer's patients currently have limited treatment options.The drug being tested is Novo's Rybelsus, a pill currently approved only for treatment of type 2 diabetes. Both Rybelsus and Novo's blockbuster drugs Ozempic and Wegovy are based on the same active ingredient, semaglutide, a GLP-1 medicine.\"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,\" Chief Scientific Officer Martin Holst Lange said in a statement.The results from the two trials of early-stage patients, called EVOKE and EVOKE+, mark another setback for the Danish drugmaker, which boomed on the success of blockbuster medicine Wegovy before slowing sales growth and a tumbling share price prompted a CEO change and mass layoffs.The setback reinforces analyst scepticism about Novo's Alzheimer's ambitions, with UBS having estimated just a 10% probability of success.The company's Executive Vice President for Product and Portfolio Strategy Ludovic Helfgott had described the Alzheimer's trials as a \"lottery ticket\" in September, a reference to its uncertain prospects yet huge potential.Alzheimer's disease and other dementias affect more than 55 million people globally. There is no cure.","news_type":1,"symbols_score_info":{"NVO":0.9}},"isVote":1,"tweetType":1,"viewCount":442,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}